Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

Inclusion Criteria for Cohort A and B: * Written informed consent must be obtained before any assessment is performed * Male and female patients between the ages of 18 to 65 (inclusive) at screening * C3G patients wit proteinuria * Able to communicate well with the investigator, to understand and comply with the requirements of the study * At screening and baseline visits, patients must weigh at least 35 kg * Supine vital signs should be within the following ranges : oral body temperature between 35.0-37.5 °C systolic blood pressure, 80-170 mm Hg diastolic blood pressure, 50-105 mm Hg pulse rate, 45 - 100 bpm . Inclusion Criteria for Cohort A: * Estimated GFR (using the CKD-EPI formula) or measured GFR ≥30 mL/min per 1.73 m2 for patients on a maximum recommended or maximum tolerated dose of an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) * UPCR ≥ 100 mg/mmol (equivalent to ≥ 1 g/24h total urinary protein excretion) * Prior to entry, all patients must have been on supportive care including a maximally tolerated dose of ACEi or ARB for at least 30 days. Inclusion Criteria for Cohort B: * No histological/laboratory/clinical signs of allorejection * If applicable, induction treatment after allotransplantation needs to be completed \>30 days before inclusion. * Transplantation of a kidney allograft \>90 days before inclusion * Patients need to be on a stable dose of immunosuppressive regimen prior to inclusion. Any approved treatments…